Humacyte's stock struggles despite FDA approval for Symvess, with financial concerns and slow adoption impacting future ...

Received U.S. Food and Drug Administration (FDA) approval of Symvess™ (acellular tissue engineered vessel-tyod) for the treatment of extremity ...

Autologous arteriovenous access is the key to long-term success with hemodialysis and is strongly supported by the National Kidney Foundation's Dialysis Outcomes Quality Initiative guidelines.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

DURHAM, N.C., March 28, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...

DURHAM, N.C., March 25, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at ...

A recent study from National Taiwan University Hospital shows that apixaban, a blood-thinning medication, can help prevent ...

Sarasota Memorial Hospital is one of ten research sites studying a new device to reduce bleeding complications in hemodialysis patients. The InnAVasc graft allows for immediate hemodialysis after ...

There is a considerable clinical need for alternatives to the autologous vein and artery tissues used for vascular reconstructive surgeries such as CABG, lower limb bypass, arteriovenous shunts ...